Loading provider…
Loading provider…
Neurology Physician in Los Alamitos, CA
NPI: 1013959097Primary Practice Location
UCI HEALTH - LOS ALAMITOS
3751 Katella Ave, Los Alamitos, CA
Primary Employer
David A. Rosenberg, M.D., Inc
drdavidrosenberg.com
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1980 - 2026

American Board of Psychiatry and Neurology
Neurology
VA Greater Los Angeles Healthcare System
Residency • Neurology
1982 - 1983
UCLA David Geffen School of Medicine/UCLA Medical Center
Residency • Neurology
1980 - 1982
SUNY Downstate Health Sciences University
downstate.edu
Residency • Neurology
1979 - 1980
Medical School
Until 1978
Roger Williams Medical Center
Internship • Internal Medicine
1978 - 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 44 | 202 |
| 2 | 99291Critical care delivery critically ill or injured patient, first 30-74 minutes | 38 | 56 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 29 | 74 |
| 4 | 99292Critical care delivery critically ill or injured patient | 29 | 46 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 17 | 18 |
[Pathogenetic and therapeutic aspects of rapidly progressive glomerulonephritis].
Authors: Erdberg, A, Rosenberg, D
Journal: Harefuah
Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system.
Authors: Steven Cheung, Claude Genain, William Mobley
Publication Date: 2000-05
Lack of universality in decaying magnetohydrodynamic turbulence.
Authors: Lee, E, Brachet, M E, Pouquet, A, Mininni, P D, Rosenberg, D
Journal: Phys Rev E Stat Nonlin Soft Matter Phys
Publication Date: 2010-01-26
Lead Sponsor: Satsuma Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Dihydroergotamine
Lead Sponsor: Supernus Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: SPN-812
Lead Sponsor: Satsuma Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: Dihydroergotamine